Sort
40,608 grants matching “prostate cancer”
Targeting Neuroendocrine Prostate Cancer Using Multi-Probe Hyperpolarized 13C MRI for Improved Treatment and Therapeutic Monitoring
$655,889John Kurhanewicz · University Of California, San Francisco · R01 · FY2020 · CA
Targeting Neuroendocrine Prostate Cancer Using Multi-Probe Hyperpolarized 13C MRI for Improved Treatment and Therapeutic Monitoring
$655,889John Kurhanewicz · University Of California, San Francisco · R01 · FY2021 · CA
Patient-Clinician Information Exchange: Determinants and Effects on Health Behavi
$655,840Robert C. Hornik · University Of Pennsylvania · P20 · FY2010 · CA
Mechanism of Action of a Novel Golgi-Targeted Anti-Cancer Agent
$655,747Seth J Field · Case Western Reserve University · R01 · FY2022 · CA
Translating HP 13C MRI as a Novel Paradigm for Assessing Drug Target Inhibition
$655,718Daniel B Vigneron · University Of California, San Francisco · R01 · FY2016 · CA
Outcomes of Prostate Cancer Androgen Deprivation Therapy
$655,686Arnold L Potosky · Georgetown University · R01 · FY2010 · CA
Long-term health consequences of birth by cesarean section
$655,685Jorge Eduardo Chavarro · Harvard School Of Public Health · R01 · FY2020 · HD
Development of Spectral Phase Contrast Micro-CT
$655,529Mini Das · University Of Houston · R01 · FY2024 · EB
Impact of Web-Based Lifestyle Interventions on Prostate Cancer Prognosis
$655,442Stacey Kenfield · University Of California, San Francisco · R01 · FY2016 · CA
Investigating the mechanisms of driver genes associated with ancestry and aggressiveness in prostate cancer
$655,337Joshua D Campbell · Boston University Medical Campus · R01 · FY2024 · CA
Chip-Scale Intraoperative Optical Navigation with Immunotargeted Upconverting Nanoparticles
$655,333Mekhail Anwar · University Of California, San Francisco · R01 · FY2023 · CA
Integrated radiomic and liquid biopsy monitoring in SWOG S1802: A phase 3 therapeutic trial for metastatic prostate cancer
$655,325Amir Goldkorn · University Of Southern California · R01 · FY2024 · CA
A novel role for EZH2 in A-to-I RNA editing in prostate cancer
$655,269Qi Cao · Northwestern University At Chicago · R01 · FY2025 · CA
HRQoL Values for Cancer Survivors: Enhancing PROMIS Measures for CER
$655,257Benjamin M Craig · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2011 · CA
Chicago Cancer Navigation Project
$655,253Steven Terry Rosen · Northwestern University At Chicago · U01 · FY2009 · CA
UBR5's mechanisms of action in tumorigenesis and immunoregulation
$655,228Xiaojing Ma · Weill Medical Coll Of Cornell Univ · R01 · FY2025 · CA
UBR5's mechanisms of action in tumorigenesis and immunoregulation
$655,228Xiaojing Ma · Weill Medical Coll Of Cornell Univ · R01 · FY2023 · CA
IDENTIFICATION OF A NOVEL MODIFIER OF LINEAGE PLASTICITY AND THERAPY RESISTANCE IN PROSTATE CANCER.
$655,212The University Of Texas Southwestern Medical Center · · FY2021 · Defense Health Agency
Biomarker Approaches to Individualizing Systemic Therapy for High Risk Prostate Cancer
$655,198Felix Yi-Chung Feng · University Of California, San Francisco · R01 · FY2023 · CA
Molecular Transitions Driving AR Loss in Double Negative Prostate Cancer
$655,070Michael C Haffner · University Of Wisconsin-Madison · P01 · FY2025 · CA
Acceptance and Commitment Therapy for Fear of Recurrence in Breast Cancer Survivors
$655,048Shelley A. Johns · Indiana University Indianapolis · R01 · FY2021 · CA
Tumor stem cells and metastatic outcomes in mouse models of prostate cancer
$655,046Kathleen Kelly · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Tissue ProcessingSequencing Facility
$654,952Cathy D Vocke · Division Of Basic Sciences - Nci · ZIC · FY2015 · CA
Validation of Biomarkers of Risk for the Early Detection of Lung Cancer
$654,948Pierre P Massion · Vanderbilt University · U01 · FY2012 · CA
Defining mechanisms underlying C9orf72-associated frontotemporal dementia with C. elegans and mammalian models
$654,898Robert G Kalb · Northwestern University At Chicago · R01 · FY2025 · NS